

What is claimed is:

1. A method of inhibiting inflammation by administration of a antibodies or antigen-binding fragments which binds at least one mammalian chemokine chosen from CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2, and CCR10 by administration to a mammal in need of anti-inflammatory intervention, of an inflammation-inhibiting effective amount of said antibodies or antigen-binding fragments in a pharmaceutically acceptable carrier.
2. The method of claim 1 wherein the carrier is a liquid.
3. The method of claim 1 wherein said mammal is human.
4. The method of claim 1 wherein the carrier is a solid support.
5. The method of claim 1 wherein said antibodies or antigen-binding fragments are derived from a human, humanized, chimeric antibody.
6. The method of claim 1 wherein said antibodies or antigen binding fragments are administered directly to tissue showing an inflammatory response tissue.
7. A method of treating a mammal with inflammatory disease by the steps of:
 - 1) exposing tissues from said mammal to differing antibodies which bind to specific chemokines,
 - 2) identifying level of expression of each chemokine based on binding of the each of the differing antibodies, and
 - 3) administering to said mammal those specific antibodies which bind to the over-expressed chemokines.
8. The method of claim 7 wherein, in step 3, the antibodies are administered directly to the affected tissue.
9. The method of claim 7 wherein, in step 3, the antibodies are administered parenterally.
10. The method of claim 7 wherein the antibodies are admin-

- istered in a liquid carrier.
11. The method of claim 7 wherein the antibodies are administered on a solid support.
12. A method of treating a mammal with inflammatory disease by the steps of:
- 5 1) identifying the level of particular chemokines using PCR,
- 2) administering to said mammal those specific antibodies which bind to the over-expressed chemokines in a pharmaceutically acceptable carrier.
- 10 13. The method of claim 12 wherein the antibodies are administered directly to the affected tissue.
14. The method of claim 12 wherein the antibodies are administered systemically.
- 15 15. The method of the invention wherein the antibodies are administered on a solid support.
15. The method of claim 12 wherein the